Advancing ADCs to the Frontline Setting - Harpreet Singh (@harpreet_md) https://t.co/FiH9r53dCf #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADCs

Highly relevant review!

What's next for biotech after JPM 2026? Tomorrow, join Endpoints News and leaders from Precision for Medicine and Precision AQ for a forward-looking discussion on the trends reshaping drug development and commercialization. November 12 at 2:30 PM ET https://t.co/ho7vVukmrR

.@harpreet_md, Chief Medical Officer at @Precision4Med, recently spoke with @CesarAPerezMD about the data from Corbus' Phase 1/2 clinical study of CRB-701 (SYS6002) presented at #ESMO25. Learn more: https://t.co/KFFq654NsC #ESMO2025 #OncologyInnovation #HeadandNeck #HNSCC

Encouraging Early Data for Next-Generation Nectin-4–Targeting ADC, CRB-701 - Harpreet Singh (@harpreet_md) https://t.co/Q0nfLR0K4p #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews

It was a packed house at the “Future Horizons, Emerging Trends & Opportunities in Cell & Gene Therapy Development” panel at Meeting on the Mesa yesterday w/ our own Deborah Phippard & Harpreet Singh. Don't miss Nick Richardson's Wed. 9:30 panel Evolving Endpoints in Gene Therapy

Precision’s VP of Clinical Development, Nicholas Richardson, DO, MPH, was on the ground at ESMO Congress 2025 in Berlin, and he shares insights on emerging trends in ADCs, cell and gene therapies, and the evolving role of MRD as a biomarker in hematologic malignancies.

How GLP-1RA drugs are reshaping patient physiology and the future of oncology Guest editorial by Deborah Phippard, PhD, chief scientific officer of @Precision4Med https://t.co/ybObeirR2V

🎯 Stay ahead in oncology regulation with OCE PULSE. This issue covers new workshop announcements, new guidance documents, and recent drug approvals from @FDAOncology. https://t.co/HTTog2cte2

https://t.co/9z6Bxh9o4U

At the World CB & CDx Summit, we’ll highlight how integrated regulatory roadmaps enable faster drug–diagnostic co-development and streamlined multi-regional submissions. Let’s connect at the event to map a path to smarter trials and faster approvals.

Tune into this discussion featuring @mhadfield30 and @harpreet_md on the FDA’s evolving draft guidance for overall survival end points, trial design, and the future of accelerated approvals in oncology. 🔗Watch here: https://t.co/jwZthBYGsG #FDA #AcceleratedApproval #Oncology

https://t.co/yh0nFmH1BG

Just wrapped the Presidential Symposium at World Lung! Several abstracts presented, including updates from both Summit Therapeutics, Inc. and Nuvalent, Inc. Proud to see biotech featured on the main stage! #IASLC #WCLC2025 #biotech

𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: @Precision4Med CMO @harpreet_md and @RepertoireIM CMO @RobertAndtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs. Full video: https://t.co/LqzHfluKgM

FDA Grants Breakthrough Therapy To Daraxonrasib For KRAS G12+ Metastatic Pancreatic Cancer - @harpreet_md @US_FDA https://t.co/PQvfTSglyK #OncoDaily #Oncology #Cancer #Health #Medicine #MedX

Can We, and Should We, Intervene Earlier in Multiple Myeloma? - Harpreet Singh (@harpreet_md) https://t.co/SP9Dl8PCbH #Health #Oncology #OncoDaily #Medicine #Cancer @CancerWorldmag

We do progress in small cell lung cancer, but still long way to go !

https://t.co/Pui8BKsIP4

FDA grants accelerated approval to a treatment for KRAS-mutated recurrent low-grade serous ovarian cancer. https://t.co/JTAzf2YcxA